000078 Shenzhen Neptunus Bioengineering
- 2.99
- -0.01-0.33%
Shenzhen Neptunus Bioengineering News
Shenzhen Neptunus Bioengineering (000078.SZ): The company's current medical device business is approximately 10 billion yuan in size.
Gelonghui November 13th | Shenzhen Neptunus Bioengineering (000078.SZ) stated in investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business, with relatively minor influence from policies. Therefore, the medical devices business is one of the company's key development sectors, with the current medical device business size reaching about tens of billions. In the future, the company will expand the scale of medical device distribution and agency business, aiming to transition from market agents to entities with the right to represent foreign brands, by introducing advanced technology and high-quality products from foreign brands to further enhance the company's level and competitiveness in the medical device business.
Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Neptune Biotech: Report for the third quarter of 2024
shenzhen neptunus bioengineering (000078.SZ): the net income in the first three quarters was 46.2173 million yuan, a year-on-year decrease of 47.77%.
On October 30, Gelonghui│ Shenzhen Neptunus Bioengineering (000078.SZ) released the third quarter report for 2024, with the company achieving revenue of 24.553 billion yuan in the first three quarters, a year-on-year decrease of 14.27%; net income attributable to shareholders of the listed company was 46.2173 million yuan, a year-on-year decrease of 47.77%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 19.7353 million yuan, a year-on-year decrease of 53.72%; basic earnings per share were 0.0176 yuan.
Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 18%, Even After 13% Gain This Past Week
Neptune Biotech: 2024 Semi-Annual Report Summary
Neptune Biology: 2024 Semi-Annual Report
Shenzhen Neptunus Bioengineering (000078.SZ): the net income in the first half of the year was 45.4098 million yuan, a decrease of 48.21% year-on-year.
Shenzhen Neptunus Bioengineering (000078.SZ) announced its semi-annual report for 2024, with a total operating income of 16.631 billion yuan, a decrease of 16.65% year-on-year; net income attributable to shareholders of the listed company was 45.4098 million yuan, a decrease of 48.21% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 38.9017 million yuan, a decrease of 28.11% year-on-year; basic earnings per share was 0.0173 yuan.
Express News | Neptunus Bioengineering Says Guangdong Provincial Government Will Be Co's Controlling Shareholder After the Deal
Express News | Neptunus Bioengineering Says Key Shareholder Shenzhen Neptunes Group Plans Sale of Stake to a Unit of Guangdong Provincial Government
Shenzhen Neptunus Bioengineering (SZSE:000078) Adds CN¥385m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 32%
BT Financial Report Instant Analysis: Shenzhen Neptunus Bioengineering's Q1 2024 Financial Data Comprehensive Analysis
Shenzhen Neptunus Bioengineering Co., Ltd. (stock code: 000078) is a high-tech enterprise focusing on research and development, production and sales of biomedical and health products. The company is committed to continuously improving its core competitiveness through technological innovation and product upgrades, and providing customers with high-quality health products and services. In the first quarter of 2024, Shenzhen Neptunus Bioengineering released its latest financial report, and this article will provide a detailed analysis of its financial data. The total assets of Shenzhen Neptunus Bioengineering in the first quarter of 2024 were 32.662 billion yuan, an increase of 1.11% compared to the end of the previous year. Attributable to the listed company.
Shenzhen Neptunus Bioengineering (SZSE:000078) Use Of Debt Could Be Considered Risky
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Business And Shares Still Trailing The Industry
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan
Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%
Haiwang Biotech (000078.SZ): It has now built a diversified, multi-level pharmaceutical product structure
Gelonghui, Feb. 5 | Haiwang Biotech (000078.SZ) said on the investor interactive platform that the company's pharmaceutical industry sector is mainly engaged in drug R&D, production and sales, with subsidiaries Haiwangfu Pharmaceutical, Jinxiang Traditional Chinese Medicine and Haiwang Zhongxin Pharmaceutical as the main platforms. The company has now built a diversified and multi-level pharmaceutical product structure. Haiwang Pharmaceutical's main business is R&D, production and sales of large infusion products, Western medicine preparations, etc.; Jinxiang Traditional Chinese Medicine is a medium-sized traditional Chinese medicine manufacturer and sales enterprise in Fujian Province, responsible for R&D, production and sales of proprietary Chinese medicines; Haiwang Zhongxin Pharmaceutical is a company integrating R&D, production and sales of pharmaceutical products
Shenzhen Neptunus Bioengineering (SZSE:000078) Has A Somewhat Strained Balance Sheet
Why Investors Shouldn't Be Surprised By Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Low P/S
Neptune Biotech (000078.SZ): NEP018 of NEP018 of NEP018 from NEP018 was approved by the US FDA to enter human clinical trials
Gelonghui, December 29丨Haiwang Biotech (000078.SZ) announced that the company's wholly-owned subsidiary Shenzhen Haiwang Pharmaceutical Technology Research Institute Co., Ltd. (“Haiwang Pharmaceutical Research Institute”) recently received a written notice from the US Food and Drug Administration to approve NEP018, a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and with independent intellectual property rights, to carry out human clinical trials of phase I drugs in the US. NEP018 is a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and has independent intellectual property rights. Comprehensive non-clinical study showed that NEP018 was effective against VEGF
Analysis
Price Target
No Data
No Data